Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.51 |
| ▸ | HTT | P42858 | 3/20 | 0.47 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | KCNJ11 | Q14654 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.39 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.39 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1164037 | 0.83 | KCNJ11 (0.55) | LMNAHTTTRPA1MEN1KMT2A | |
| SCHEMBL1244526 | 0.80 | HTT (0.49) | LMNAHTTTRPA1MEN1KMT2A | |
| SCHEMBL1922849 | 0.76 | MEN1 (0.61) | LMNAHTTTRPA1MEN1KMT2A | |
| SCHEMBL12156708 | 0.74 | KMT2A (0.70) | LMNAHTTTRPA1MEN1KMT2A | |
| SCHEMBL1923339 | 0.72 | MAPT (0.73) | LMNAHTTMEN1KMT2AMAPT | |
| SCHEMBL12835446 | 0.71 | MEN1 (0.52) | LMNAHTTMEN1KMT2AMAPT | |
| SCHEMBL11554329 | 0.71 | HTT (0.55) | LMNAHTTTRPA1MEN1KMT2A | |
| SCHEMBL1923171 | 0.70 | MAPT (0.51) | LMNAHTTTRPA1MEN1KMT2A | |
| SCHEMBL12156714 | 0.69 | KMT2A (0.88) | LMNAHTTTRPA1MEN1KMT2A | |
| SCHEMBL12156716 | 0.68 | MEN1 (0.59) | LMNAHTTTRPA1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120190694-A1 | SELECTIVE SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS | ALLERGAN, INC. (US) | 2012-07-26 | — | — | US | disclosed |
| EP-2464629-A1 | SELECTIVE SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS | Allergan, Inc. (US) | 2012-06-20 | — | — | EP | disclosed |
| US-8168795-B2 | Selective sphingosine-1-phosphate receptor antagonists | ALLERGAN, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| WO-2011028927-A1 | SELECTIVE SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS | ALLERGAN, INC. (US) | 2011-03-10 | — | — | WO | disclosed |
| WO-2011019681-A1 | SELECTIVE SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS | ALLERGAN, INC. (US) | 2011-02-17 | — | — | WO | disclosed |
| US-20110039866-A1 | SELECTIVE SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS | ALLERGAN, INC. (US) | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190694-A1 | SELECTIVE SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS | S1PR3, S1PR1, S1PR2 | LMNA 3313/4885HTT 3427/4885TRPA1 1127/4885 |
| US-20110039866-A1 | SELECTIVE SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS | S1PR3, S1PR1, S1PR2 | LMNA 3313/4885HTT 3427/4885TRPA1 1127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.